{"url_path":"/sec/vtgn/8-k/2026-05-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-032935-index.html","accession_number":"0001628280-26-032935","cik":"0001411685","ticker":"VTGN","issuer_name":"Vistagen Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-032935-index.html","primary_entity_key":"0001411685","primary_entity_name":"Vistagen Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d)Exhibits Index\n\nExhibit No.Description\n\n  \n\n99.1\n[Press Release issued by Vistagen Therapeutics, Inc., dated May 8, 2026](pal-4lplvprex991.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSignatures\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n Vistagen Therapeutics, Inc.\n\nDate: May 8, 2026By:/s/ Shawn K. Singh\n\n  Shawn K. Singh\nPresident and Chief Executive Officer"}